Vir Biotechnology/$VIR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vir Biotechnology
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Ticker
$VIR
Sector
Primary listing
Employees
408
Headquarters
Website
VIR Metrics
BasicAdvanced
$814M
-
-$4.01
1.28
-
Price and volume
Market cap
$814M
Beta
1.28
52-week high
$14.45
52-week low
$4.16
Average daily volume
1.3M
Financial strength
Current ratio
7.006
Quick ratio
5.771
Long term debt to equity
9.858
Total debt to equity
9.858
Profitability
EBITDA (TTM)
-554.708
Gross margin (TTM)
-2,426.85%
Net profit margin (TTM)
-2,895.94%
Operating margin (TTM)
-2,980.39%
Effective tax rate (TTM)
-0.05%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-24.73%
Return on equity (TTM)
-46.22%
Valuation
Price to revenue (TTM)
42.361
Price to book
0.86
Price to tangible book (TTM)
0.88
Price to free cash flow (TTM)
-1.726
Free cash flow yield (TTM)
-57.95%
Free cash flow per share (TTM)
-3.396
Growth
Revenue change (TTM)
-75.91%
Earnings per share change (TTM)
11.91%
3-year revenue growth (CAGR)
-79.19%
3-year earnings per share growth (CAGR)
-20.27%
What the Analysts think about VIR
Analyst ratings (Buy, Hold, Sell) for Vir Biotechnology stock.
Bulls say / Bears say
Vir Biotechnology successfully dosed the first patient in its ECLIPSE Phase 3 chronic hepatitis delta program in March 2025, a trial granted U.S. FDA Breakthrough and Fast Track designations as well as EMA PRIME and Orphan Drug designations to expedite development (Nasdaq)
Early Phase 1 data for its PRO-XTEN™ dual-masked T-cell engagers showed tumor shrinkage in 50% of participants with HER2-positive solid tumors (VIR-5818) and PSA reductions in 100% of mCRPC patients with 58% achieving PSA50 (VIR-5500), validating its oncology platform’s potential (Nasdaq)
As of March 31, 2025, Vir held approximately $1.0 billion in cash and investments, providing a projected financial runway into mid-2027 to support its key clinical and preclinical programs (Nasdaq)
Total revenue plummeted 95% year-over-year to $3.03 million in Q1 2025, driven by the expiration of GSK collaboration rights and underscoring a lack of recurring revenue sources (Nasdaq)
Vir’s net loss widened to $0.88 per share in Q1 2025 from $0.48 a year earlier, reflecting an 85% increase in losses and intensifying funding requirements (Nasdaq)
Net cash used in operating activities remained high at $78 million in Q1 2025 despite minimal revenue, accelerating cash burn that could truncate its mid-2027 runway if programs face setbacks (Panabee)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.
VIR Financial Performance
Revenues and expenses
VIR Earnings Performance
Company profitability
VIR News
AllArticlesVideos
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Business Wire2 months ago
Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta
Business Wire2 months ago
Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vir Biotechnology stock?
Vir Biotechnology (VIR) has a market cap of $814M as of October 14, 2025.
What is the P/E ratio for Vir Biotechnology stock?
The price to earnings (P/E) ratio for Vir Biotechnology (VIR) stock is 0 as of October 14, 2025.
Does Vir Biotechnology stock pay dividends?
No, Vir Biotechnology (VIR) stock does not pay dividends to its shareholders as of October 14, 2025.
When is the next Vir Biotechnology dividend payment date?
Vir Biotechnology (VIR) stock does not pay dividends to its shareholders.
What is the beta indicator for Vir Biotechnology?
Vir Biotechnology (VIR) has a beta rating of 1.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.